CN101884808A - 局部抗凝及细胞捕获的脱细胞骨基质复合材料及制备方法 - Google Patents
局部抗凝及细胞捕获的脱细胞骨基质复合材料及制备方法 Download PDFInfo
- Publication number
- CN101884808A CN101884808A CN2010102352736A CN201010235273A CN101884808A CN 101884808 A CN101884808 A CN 101884808A CN 2010102352736 A CN2010102352736 A CN 2010102352736A CN 201010235273 A CN201010235273 A CN 201010235273A CN 101884808 A CN101884808 A CN 101884808A
- Authority
- CN
- China
- Prior art keywords
- cell
- bone
- composite
- heparin
- bone matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 42
- 210000002805 bone matrix Anatomy 0.000 title claims abstract description 27
- 238000007710 freezing Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 42
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 37
- 239000011159 matrix material Substances 0.000 claims abstract description 21
- 229920001661 Chitosan Polymers 0.000 claims abstract description 19
- 239000011248 coating agent Substances 0.000 claims abstract description 19
- 238000000576 coating method Methods 0.000 claims abstract description 19
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 16
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 16
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- -1 sulfuric acid polysaccharide Chemical class 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 52
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 34
- 229960002897 heparin Drugs 0.000 claims description 34
- 229920000669 heparin Polymers 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 20
- 210000002744 extracellular matrix Anatomy 0.000 claims description 19
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 11
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 11
- 239000008351 acetate buffer Substances 0.000 claims description 11
- 238000007654 immersion Methods 0.000 claims description 8
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 4
- 230000010100 anticoagulation Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 235000011149 sulphuric acid Nutrition 0.000 claims description 4
- 239000001117 sulphuric acid Substances 0.000 claims description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 14
- 210000001519 tissue Anatomy 0.000 abstract description 12
- 230000007547 defect Effects 0.000 abstract description 3
- 230000009881 electrostatic interaction Effects 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 11
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000002429 anti-coagulating effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001951 hemoperfusion Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000012769 display material Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000001420 photoelectron spectroscopy Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010235273.6A CN101884808B (zh) | 2010-07-23 | 2010-07-23 | 局部抗凝及细胞捕获的脱细胞骨基质复合材料及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010235273.6A CN101884808B (zh) | 2010-07-23 | 2010-07-23 | 局部抗凝及细胞捕获的脱细胞骨基质复合材料及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101884808A true CN101884808A (zh) | 2010-11-17 |
CN101884808B CN101884808B (zh) | 2016-02-03 |
Family
ID=43071004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010235273.6A Expired - Fee Related CN101884808B (zh) | 2010-07-23 | 2010-07-23 | 局部抗凝及细胞捕获的脱细胞骨基质复合材料及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101884808B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893824A (zh) * | 2014-04-16 | 2014-07-02 | 重庆大学 | 一种具有不同刚度三维骨组织工程支架材料及其制备方法 |
CN104013998A (zh) * | 2014-05-26 | 2014-09-03 | 宁波大学 | 一种具有组织学结构的人工食道的制备方法 |
CN106267369A (zh) * | 2016-08-05 | 2017-01-04 | 华中科技大学同济医学院附属协和医院 | 一种人造血管及其制备方法 |
CN110124106A (zh) * | 2019-04-19 | 2019-08-16 | 上海交通大学 | 一种表面修饰的去细胞生物组织材料及其制备方法与应用 |
CN113425915A (zh) * | 2021-05-28 | 2021-09-24 | 宁波市第一医院 | 一种抗凝材料及其制备方法和应用 |
CN116392646A (zh) * | 2021-12-28 | 2023-07-07 | 诺一迈尔(苏州)医学科技有限公司 | 一种引导骨再生屏障膜 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1836743A (zh) * | 2006-04-28 | 2006-09-27 | 武汉理工大学 | 多孔、分层、三维空间多级结构的组织支架材料及其制备方法 |
CN101371932A (zh) * | 2008-11-13 | 2009-02-25 | 广州知光生物科技有限公司 | 生物型人工颌骨 |
-
2010
- 2010-07-23 CN CN201010235273.6A patent/CN101884808B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1836743A (zh) * | 2006-04-28 | 2006-09-27 | 武汉理工大学 | 多孔、分层、三维空间多级结构的组织支架材料及其制备方法 |
CN101371932A (zh) * | 2008-11-13 | 2009-02-25 | 广州知光生物科技有限公司 | 生物型人工颌骨 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893824A (zh) * | 2014-04-16 | 2014-07-02 | 重庆大学 | 一种具有不同刚度三维骨组织工程支架材料及其制备方法 |
CN104013998A (zh) * | 2014-05-26 | 2014-09-03 | 宁波大学 | 一种具有组织学结构的人工食道的制备方法 |
CN106267369A (zh) * | 2016-08-05 | 2017-01-04 | 华中科技大学同济医学院附属协和医院 | 一种人造血管及其制备方法 |
CN106267369B (zh) * | 2016-08-05 | 2019-05-31 | 华中科技大学同济医学院附属协和医院 | 一种人造血管及其制备方法 |
CN110124106A (zh) * | 2019-04-19 | 2019-08-16 | 上海交通大学 | 一种表面修饰的去细胞生物组织材料及其制备方法与应用 |
CN113425915A (zh) * | 2021-05-28 | 2021-09-24 | 宁波市第一医院 | 一种抗凝材料及其制备方法和应用 |
CN113425915B (zh) * | 2021-05-28 | 2022-08-09 | 宁波市第一医院 | 一种抗凝材料及其制备方法和应用 |
CN116392646A (zh) * | 2021-12-28 | 2023-07-07 | 诺一迈尔(苏州)医学科技有限公司 | 一种引导骨再生屏障膜 |
Also Published As
Publication number | Publication date |
---|---|
CN101884808B (zh) | 2016-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Neishabouri et al. | Decellularization in tissue engineering and regenerative medicine: evaluation, modification, and application methods | |
CN101884808A (zh) | 局部抗凝及细胞捕获的脱细胞骨基质复合材料及制备方法 | |
US8445278B2 (en) | Process for producing decellularized biological tissues | |
Destefani et al. | Advances in the knowledge about kidney decellularization and repopulation | |
CN105963785B (zh) | 一种基于脂肪干细胞膜片的脱细胞基质材料及其制备方法 | |
Spina et al. | Isolation of intact aortic valve scaffolds for heart‐valve bioprostheses: extracellular matrix structure, prevention from calcification, and cell repopulation features | |
CN102198292B (zh) | 组织工程用脐带去细胞Wharton胶支架及其制备方法 | |
Baiguera et al. | Dynamic decellularization and cross-linking of rat tracheal matrix | |
CN105392506B (zh) | 植入物和通过负压下使组织去细胞化来制造植入物的方法 | |
Dai et al. | Modifying decellularized aortic valve scaffolds with stromal cell-derived factor-1α loaded proteolytically degradable hydrogel for recellularization and remodeling | |
Weymann et al. | Reendothelialization of human heart valve neoscaffolds using umbilical cord-derived endothelial cells | |
Yu et al. | The rat pancreatic body tail as a source of a novel extracellular matrix scaffold for endocrine pancreas bioengineering | |
CN104888274A (zh) | 一种具有天然水平糖胺聚糖的脱细胞基质及其制备与应用 | |
Yang et al. | Performance of different three-dimensional scaffolds for in vivo endochondral bone generation | |
CN104640577B (zh) | 亲水性的含有磷酸根基团的脱水且部分纯化的骨骼置换材料 | |
Zhu et al. | Current advances in the development of decellularized plant extracellular matrix | |
CN106492288A (zh) | 可注射的脱细胞脂肪基质微粒及其在植入剂中的应用 | |
CN101327338B (zh) | 多孔的保留有生物活性因子的膀胱无细胞基质及制备方法 | |
CN111840647B (zh) | 可吸收屏障膜及其制备方法 | |
Nooshin et al. | Effects of different perfusing routes through the portal vein, hepatic vein, and biliary duct on whole rat liver decellularization | |
US20210128785A1 (en) | Bioartificial vascular pancreas | |
CN109481053A (zh) | 一种脱位牙仿生三维支架膜及其制备方法 | |
Wang et al. | The research of acellular pancreatic bioscaffold as a natural 3-dimensional platform in vitro | |
Rizzi et al. | Engineering Efforts to Refine Compatibility and Duration of Aortic Valve Replacements: An Overview of Previous Expectations and New Promises | |
CN107281551A (zh) | 冰冻法制备肝脏生物支架的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: FIELD MILLITARY SURGERY INST. OF THIRD MEDICAL UNI Free format text: FORMER OWNER: NO.3 HOSPITAL ATTACHED TO NO.3 MILITARY MEDICAL UNIV., P.L.A.;NO.3 HOSPITAL ATTACHED TO NO.3 MILITAR Effective date: 20140818 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Bo Inventor after: Yang Zailiang Inventor after: Sun Xinjun Inventor after: Wang Zhengguo Inventor after: Zhang Shichang Inventor after: Zhang Lianyang Inventor after: Zhou Jihong Inventor after: Ren Mingliang Inventor after: Zhu Peifang Inventor after: Liu Dawei Inventor before: Sun Xinjun Inventor before: Yang Zailiang Inventor before: Zhang Bo Inventor before: Wang Zhengguo Inventor before: Zhang Shichang Inventor before: Zhang Lianyang Inventor before: Zhou Jihong Inventor before: Ren Mingliang Inventor before: Zhu Peifang Inventor before: Liu Dawei |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SUN XINJUN ZHANG BO WANG ZHENGGUO ZHANG SHICHANG ZHANG LIANYANG ZHOU JIHONG REN MINGLIANG ZHU PEIFANG LIU DAWEI YANG ZAILIANG TO: ZHANG BO SUN XINJUN WANG ZHENGGUO ZHANG SHICHANG ZHANG LIANYANG ZHOU JIHONG REN MINGLIANG ZHU PEIFANG LIU DAWEI YANG ZAILIANG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140818 Address after: Chongqing city Yuzhong District Daping 400042 Yangtze River Branch No. 10 Applicant after: Field Millitary Surgery Inst. of Third Medical Univ. P. L. A. Address before: Chongqing city Yuzhong District Daping 400042 Yangtze River Branch No. 10 Applicant before: The Third Affiliated Hospital of Third Military Medical University of PLA |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160203 Termination date: 20160723 |
|
CF01 | Termination of patent right due to non-payment of annual fee |